Literature DB >> 2431918

Multiple tachykinin binding sites in peripheral tissues and in brain.

C M Lee, N J Campbell, B J Williams, L L Iversen.   

Abstract

Tachykinin binding sites in guinea pig urinary bladder (GPUB), rat salivary gland (RSG), hamster urinary bladder (HUB), rat vas deferens (RVD) and rat cerebral cortex (RCC) were compared using 125I-Bolton Hunter conjugates of substance P (125I-BHSP), eledoisin (125I-BHE) and neurokinin A (125I-BHNKA). In typical SP-P tissues (GPUB, RSG) and in RCC, SP was the most potent displacer of 125I-BHSP and [Glp6,D-Pro9]-SP(6-11) was 90 times less active than [Glp6,L-Pro9]-SP(6-11) while SP methyl ester (SPOMe) was 5-10 times more active than the Bolton Hunter conjugate of SPOMe (I-BHSPOMe). On the other hand, in typical SP-E tissues (HUB, RVD), neurokinin A was most potent in displacing 125I-BHE and [Glp6,D-Pro9]-SP(6-11) was over 300 times more active than [Glp6,L-Pro9]-SP(6-11) while SPOMe was 160 times less active than I-BHSPOMe. In rat cerebral cortex, the rank order of potency of tachykinins and related analogues in displacing 125I-BHE was distinct from that of peripheral SP-E sites, with neurokinin B being the most potent displacer, and SPOMe was over 1,000 times more active than I-BHSPOMe; 125I-BHE binding sites in CNS may represent a third category of tachykinin receptor, designated SP-N.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2431918     DOI: 10.1016/0014-2999(86)90270-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  35 in total

1.  Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors.

Authors:  A T McKnight; J J Maguire; N J Elliott; A E Fletcher; A C Foster; R Tridgett; B J Williams; J Longmore; L L Iversen
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

2.  Pharmacological properties of a potent and selective nonpeptide substance P antagonist.

Authors:  C Garret; A Carruette; V Fardin; S Moussaoui; J F Peyronel; J C Blanchard; P M Laduron
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

3.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

Review 4.  Autoradiographical and immunohistochemical analysis of receptor localization in the central nervous system.

Authors:  J G Chabot; S Kar; R Quirion
Journal:  Histochem J       Date:  1996-11

5.  Further evidence for the existence of NK2 tachykinin receptor subtypes.

Authors:  R Patacchini; M Astolfi; L Quartara; P Rovero; A Giachetti; C A Maggi
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

6.  Solubilization and characterization of substance P-binding sites from chick brain membranes.

Authors:  H P Too; M R Hanley
Journal:  Biochem J       Date:  1988-06-01       Impact factor: 3.857

7.  Characterization of a tachykinin peptide NK2 receptor transfected into murine fibroblast B82 cells.

Authors:  P L van Giersbergen; S A Shatzer; A K Henderson; J Lai; S Nakanishi; H I Yamamura; S H Buck
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

8.  Primary structure and receptor-binding properties of a neurokinin A-related peptide from frog gut.

Authors:  Y Wang; T Badgery-Parker; S Lovas; N Chartrel; H Vaudry; E Burcher; J M Conlon
Journal:  Biochem J       Date:  1992-11-01       Impact factor: 3.857

9.  FR 113680: a novel tripeptide substance P antagonist with NK1 receptor selectivity.

Authors:  H Morimoto; M Murai; Y Maeda; D Hagiwara; H Miyake; M Matsuo; T Fujii
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

10.  The interaction of the NK1 receptor antagonist CP-96,345 with L-type calcium channels and its functional consequences.

Authors:  S Guard; S J Boyle; K W Tang; K J Watling; A T McKnight; G N Woodruff
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.